RenovoRx, Inc. (RNXT) stock

RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30146% above fair value

$1.16−0.06 (-4.92%)

Close on Nov 12, 2026Market cap $52.35MP/E –Yield –

RenovoRx r&d expenses

Research and development expenses are spending on new products and technology.

RenovoRx's R&D Expenses for the twelve months ending Sep 30, 2026 was $5.17M, down 18.3% year over year. For fiscal 2025 it was $6.27M, up 4.0% from the year before. The highest annual figure on record is $6.27M in fiscal 2025.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$6.27M	+4.0%
FY2024	Dec 31, 2024	$6.03M	+6.3%
FY2023	Dec 31, 2023	$5.67M	+31.8%
FY2022	Dec 31, 2022	$4.30M	+41.5%
FY2021	Dec 31, 2021	$3.04M	+27.4%
FY2020	Dec 31, 2020	$2.39M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$1.24M	-26.4%
Q2 FY2026	Jun 30, 2026	$1.20M	-15.8%
Q1 FY2026	Mar 31, 2026	$1.23M	-25.2%
Q4 FY2025	Dec 31, 2025	$1.50M	-4.8%
Q3 FY2025	Sep 30, 2025	$1.69M	+2.1%
Q2 FY2025	Jun 30, 2025	$1.43M	-7.5%
Q1 FY2025	Mar 31, 2025	$1.64M	+30.6%
Q4 FY2024	Dec 31, 2024	$1.58M	+103.4%
Q3 FY2024	Sep 30, 2024	$1.65M	+1.3%
Q2 FY2024	Jun 30, 2024	$1.54M	-19.9%
Q1 FY2024	Mar 31, 2024	$1.26M	-6.1%
Q4 FY2023	Dec 31, 2023	$775.00K	-0.1%
Q3 FY2023	Sep 30, 2023	$1.63M	+92.6%
Q2 FY2023	Jun 30, 2023	$1.93M	+38.5%
Q1 FY2023	Mar 31, 2023	$1.34M	+3.8%
Q4 FY2022	Dec 31, 2022	$776.00K	-29.5%
Q3 FY2022	Sep 30, 2022	$846.00K	+10.3%
Q2 FY2022	Jun 30, 2022	$1.39M	+159.3%
Q1 FY2022	Mar 31, 2022	$1.29M	+103.0%
Q4 FY2021	Dec 31, 2021	$1.10M	+143.6%
Q3 FY2021	Sep 30, 2021	$767.00K	+5.5%
Q2 FY2021	Jun 30, 2021	$536.00K	–
Q1 FY2021	Mar 31, 2021	$635.00K	–
Q4 FY2020	Dec 31, 2020	$452.00K	–
Q3 FY2020	Sep 30, 2020	$727.00K	–